Navigation Links
Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
Date:7/7/2011

AMSTERDAM, July 7, 2011 /PRNewswire/ --


Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it has filed a request for re-examination of the Marketing Authorisation Application for Glybera® with the European Medicines Agency. Glybera is a gene therapy for the genetic disorder lipoprotein lipase deficiency. The Company expects that the re-examination of the dossier will be completed by the end of 2011.

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. The company's lead product Glybera®, a gene therapy for lipoprotein lipase deficiency (LPLD), is currently under review by the European Medicines Agency (EMA). If approved, Glybera will be the first gene therapy product to be marketed in Europe. AMT also has a product pipeline of several gene therapy products in development for hemophilia B, Duchenne muscular dystrophy, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows AMT to pursue its strategy of focusing on this sector of the industry.  AMT was founded in 1998 and is based in Amsterdam. Further information can be found at http://www.amtbiopharma.com.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "st
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
2. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
3. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
4. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
5. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
6. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
7. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
8. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
9. Elsevier and Molecular Connections Develop Two New Applications on SciVerse Applications
10. Biochemist and Geneticist Ronald W. Davis Receives $500,000 Gruber Genetics Prize for Pioneering Work in the Development of Biotechnologies that Have Significantly Advanced the Fields of Molecular Genetics and Genomics
11. NIH grant ratchets up ASU research in molecular motors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... YORK , Sept. 1, 2015 /PRNewswire-USNewswire/ ... of cancer death in American men. One ... cancer and 233,000 new cases are diagnosed annually. ... experts are using a powerful new technique, ... small and large cancer lesions, treating only the ...
(Date:9/1/2015)... ... September 01, 2015 , ... In her thought provoking debut novel ‘ ... a not-so-distant future faced with an Ebola pandemic that is on the cusp of ... to enter the world of counterterrorism, and who continues to appear in this series ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... , Equine cervical facet joint problems can be caused by injuries and ... cause impingement of nerve roots or of the spinal cord itself. This can ...
(Date:9/1/2015)... ... 01, 2015 , ... Leading CEOs, CSOs, CMOs, and heads ... join prominent academics and key investors for Neuro Advance Boston, October 14, 2015 ... , Neuro Advance Boston focuses on the latest developments and opportunities in ...
Breaking Biology Technology:September Is Prostate Cancer Awareness Month 2September Is Prostate Cancer Awareness Month 3September Is Prostate Cancer Awareness Month 4Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 3VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 3Neuro Advance Boston Brings Together Leading Neuroscience Experts on October 14 at Harvard Medical School 2
... 2012 ValGenesis, Inc., a world-class provider of ... its innovative ValGenesis Suite 2.5 has achieved SAP ... platform. Attaining this certified integration status deepens ValGenesis, ... The SAP Integration and Certification Center (SAP ...
... 2012  VolitionRX Limited (VNRX.OB), a life sciences company focused ... with Abcodia, a specialist company spun out from University ... to Abcodia,s biobank of over 5,000,000 human serum samples ... The samples, which were collected by scientists at UCL, ...
... ago, MIT professors Robert Langer and Michael Cima had ... that would deliver drugs after implantation in a patient,s ... MicroCHIPS Inc. reported that they have successfully used such ... drug normally given by injection. The results, published ...
Cached Biology Technology:ValGenesis Suite 2.5 Certified by SAP as Powered by SAP NetWeaver® 2ValGenesis Suite 2.5 Certified by SAP as Powered by SAP NetWeaver® 3Volition Signs Collaboration Agreement With Abcodia 2Volition Signs Collaboration Agreement With Abcodia 3Successful human tests for first wirelessly controlled drug-delivery chip 2Successful human tests for first wirelessly controlled drug-delivery chip 3
(Date:8/20/2015)... , Aug. 20, 2015 The wearable ... that are active and healthy. However, wearable technology ... hospital environment to help improve diagnostic capabilities and ... from the Wearable Technologies Conference 2015 , ... applications for wearables in healthcare.    ...
(Date:8/18/2015)... PRINCETON, N.J. , Aug. 18, 2015 ... be a key contributor to the Submission ... hosted by IRISS, a non-profit forum. Dedicated to ... IRISS provides a neutral platform for industry, ... to share information and work towards a ...
(Date:8/12/2015)... SPRINGS, Florida , August 12, 2015 ... the pace of mobile payment innovation and advanced biometrics ... to replace the way consumers rely on using their ... ahead with reinventing the future for payment services led ... (NASDAQ: NXTD ), :  Google, Inc. (NASDAQ: ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6
... WASHINGTON A recently published paper by two George Washington University ... habitually barefoot people in Kenya due to speed and other ... ground. These results are counter to the belief that barefoot ... a Ph.D. student in the Hominid Paleobiology doctoral program at ...
... Fellow Anne Ruffing has engineered two strains of cyanobacteria ... fuels, but she has also found that the process ... might be one way to reduce the nation,s dependence ... they are powered by sunlight. They also could reduce ...
... nearly a century ago changed diabetes from a death ... that includes researchers from Case Western Reserve University School ... dramatic improvements in the lives of people managing diabetes. ... interacts with cells, the international group of scientists finally ...
Cached Biology News:GW researchers find variation in foot strike patterns in predominantly barefoot runners 2Engineering alternative fuel with cyanobacteria 2Engineering alternative fuel with cyanobacteria 3After decades of research, scientists unlock how insulin interacts with cells 2After decades of research, scientists unlock how insulin interacts with cells 3
...
Sheep polyclonal to Quinolone ( Abpromise for all tested applications). Antigen: Norfloxacin(N)conjugated to BSA...
Certified U.S. origin. Bovine Serum:, *Certified U.S. origin. Available raw, nonsterile filtered, or sterile filtered. , , *Sterility tested , , *Low Hemoglobin levels , , *Mycoplasma testing upon...
...
Biology Products: